Intervention: Pazopanib Hydrochloride
Trial phase: Phase 1 | Phase 2
SMILES: Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: This is a single site, open label, safety and efficacy study of pazopanib (5mg/ml) where all 20 patients with corneal neovascularization in a single arm will receive pazopanib in one eye.

Frequency and Duration: 4 times per day for 3 weeks
Eligibility criteria:
Inclusion Criteria:

Ability to provide written informed consent
Ability to comply with study assessments and study requirements (for example, able to open the eye drop foil-wrap packaging and eye drop vials, willing to adhere to the daily dosing schedule) for the full duration of study
Age > 18 years
Patients with superficial or deep corneal neovascularization that extends farther than 1 mm from the limbus
Patients are in stable overall health
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin ≤ 1.5x upper limit of normal (ULN) or isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%
Single QTcF < 450 msec; or QTcF < 480 msec in subjects with Bundle Branch Block
A female is eligible to enter and participate in this study if she is of Non-childbearing potential (i.e., physiologically incapable of becoming pregnant),

Exclusion Criteria:

Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
History of any clotting disorder, including predisposition to hypercoagulation or any previous thromboembolic event
Major surgery within 1 month of screening
Has received treatment with anti-VEGF agents (topical, intraocular or systemic) within 60 days of study entry. This includes both approved and investigational treatments.
Has received investigational therapy within 60 days prior to study entry
Concurrent enrollment in another clinical investigational medicinal product or device study
Concurrent use of anti-VEGF agents
Corneal or ocular surface infection within 30 days prior to study entry
Full thickness or lamellar keratoplasty within 90 days prior to study entry
Other ocular surgeries within 60 days prior to study entry
Ocular or periocular malignancy
Soft Contact lens (excluding bandage contact lens) use within 2 weeks prior to study entry
Persistent epithelial defect (>1mm and ≥14 days duration) within 2 weeks prior to study entry
Intravitreal or periocular steroids within 4 weeks prior to study entry
Change in dose/frequency of topical steroids and/or nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to study entry
Poorly controlled Hypertension: systolic blood pressure (BP) > 150 or diastolic BP > 90
Medical history of uncontrolled diabetes mellitus, with hemoglobin A1c (HbA1c) >7%

Women 45 years of age or younger that are of child bearing potential as defined by:

No history of a hysterectomy
No history of a bilateral oophorectomy (ovariectomy)
No history of a bilateral tubal ligation
Not post-menopausal
Subjects using hormone replacement therapy (HRT) that have experienced total cessation of menses for ≤ 1 year, OR, in questionable cases, have a follicle stimulating hormone (FSH) value <40 mIU/mL and an estradiol value > 40pg/mL (>140 pmol/L) OR have documented evidence OR have had documented evidence of menopause based on FSH and estradiol concentrations prior to initiation of HRT. Signs of current infection, including fever and current treatment with antibiotics
Participation in another simultaneous medical investigation or trial STUDY